55112-42-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55112-42-0,4-Methyl-1-piperazinecarbonyl Chloride Hydrochloride,as a common compound, the synthetic route is as follows.
Benzyl N-(4-methylpiperazin-1-ylcarbonyl)glycinate may be prepared in the following manner: 4.2 cm3 of triethylamine and 3.02 g of benzyl glycinate hydrochloride are added, at 20 C., to 3 g of 4-methylpiperazin-1-ylcarbonyl chloride hydrochloride in solution in 150 cm3 of tetrahydrofuran. After stirring for 16 hours at 60 C., the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) and the residue is taken up in 70 cm3 of dichloromethane. The organic phase is successively washed with twice 100 cm3 of a saturated aqueous sodium bicarbonate solution and 70 cm3 of water, and then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) to give 1.9 g of benzyl N-(4-methylpiperazin-1-ylcarbonyl)-glycinate in the form of a white solid. 1H NMR spectrum (400 MHz, (CD3)2SO d6, delta in ppm): 2.18 (s: 3H); 2.25 (t, J=5 Hz: 4H); 3.30 (t, J=5 Hz: 4H); 3.80 (d, J=6 Hz: 2H); 5.13 (s: 2H); 7.02 (t, J=6 Hz: 1H); from 7.30 to 7.45 (mt: 5H).
As the paragraph descriping shows that 55112-42-0 is playing an increasingly important role.
Reference£º
Patent; Aventis Pharma S.A.; US6569854; (2003); B1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics